Who may participate
This study is seeking healthy breastfeeding female participants.
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can fully determine if you qualify to enroll in the study.
What to expect
The study is planned to last for approximately 9 weeks.
Several examinations or procedures will be required in connection with the study:
1. A screening examination, during which you will sign a COVID ICD and the study ICD;
2. COVID-19 assessments during residence in the PCRU
3. One treatment period organized of 5 days and 4 nights in the PCRU (from Day -1 to Day 4).
4. The follow-up phone call will take place 28 to 35 days after the last administration of the study medicine.
You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.
a follow-up call at the end of the study
€ 1.670 upon completion of the study, €120 Covid and transportation fees
Interested in participating?
New to clinical research? If you’re interested in becoming a participant or need more information on the registration process, please complete and submit the registration form. We will contact you as soon as possible
Already in our database? If you’d like to subscribe for this study, please contact us by phone.
Studies (recruiters) For more information, call 0800/99.256 (from abroad: 0032/2. 556.70.02 or 00800/2636.2636 from France, The Netherlands, Germany, UK) or email us.
Personal data means any information relating to you as a natural person such as for example your name, your date of birth, your telephone number or information relating to your health or your medical condition.
The personal data you share with us when completing the registration form is collected by the Brussels PCRU in order to send you the relevant literature and the medical questionnaire. It will be processed in a strictly confidential manner and in conformity with all applicable legislations, especially the European and Belgian laws applicable to clinical trials, and the European and Belgian laws applicable to personal data protection.
Personal data protection is very important to our clinical research unit. That’s why we ask that you read our Privacy Notice available at https://privacycenter.pfizer.com/en/belgium.